AOD 9604 Vs. Semaglutide: Differences, Pros & Cons

What Is GLP-1 Injection Therapy?

GLP-1 receptor agonists are prescription medications that mimic the body’s endogenous GLP-1 hormone. Originally approved for managing type2 diabetes as Ozempic® , certain GLP-1 drugs like semaglutide are also indicated for chronic weight management, approved as WeGovy®  when lifestyle changes are insufficient.

These drugs work by enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and promoting satiety, which can lead to reduced caloric intake and weight loss (Wen et al., 2024).
‍

What Is AOD 9604?

AOD 9604 is a synthetic peptide derived from a modified segment of human growth hormone (hGH). It was initially researched for its potential to stimulate lipolysis without affecting blood sugar levels. However, AOD 9604 remains unapproved by the FDA and has not undergone large-scale clinical trials to support its use in weight loss or other medical conditions.

Although some early studies in animals suggested effects on fat metabolism, the absence of robust human data prevents it from being recommended for therapeutic use.
‍

Mechanisms of Action Compared

GLP-1 Agonists (e.g., Semaglutide)
These agents may work by:

• Enhancing post-meal insulin secretion
  
• Reducing glucagon levels
  
• Slowing gastric emptying
  
• Promoting satiety and reducing caloric intake
  
  

These mechanisms not only aid glucose control but also support sustainable weight loss in patients with type 2 diabetes and obesity (Urias et al., 2023).

AOD 9604
Lab and animal models have examined its effect on:

• Lipolysis – Breakdown of stored fat
  
  
• Lipogenesis – Inhibition of fat cell formation
  
  

However, these effects are not validated in human clinical trials. Therefore, its role in metabolism remains speculative.

‍

Weight Loss Effectiveness Compared

‍

‍

Safety Profiles Compared

AOD 9604

• No long-term safety data
  
• Product quality may vary
  
• “GRAS” status applies only to food additives, not injectable or therapeutic use
  
  

Semaglutide

• FDA-regulated manufacturing
  
• Common side effects: nausea, vomiting, and constipation
  
• Serious adverse effects are rare but require monitoring (Traverse et al., 2024)
  
  

Cost Comparison

‍

‍

Pros and Cons Summary

AOD 9604

Pros

• Potential fat metabolism effects (theoretical)
  
• Lower cost
  
• Investigational interest
  
  

Cons

• No FDA approval
  
• Lack of clinical evidence
  
• Variable quality and sourcing risks
  
• Should only be used with provider oversight
  
  

GLP-1 Injections (Semaglutide)

Pros

• efficacy in diabetes  and obesity
  
• FDA-approved as Ozempic®  for T-2 diabetes control and WeGovy® for obesity with a strong safety profile
  
• Regulated and manufactured under strict conditions
  
• May be partially covered by insurance
  
  

Cons

• Higher cost without coverage
  
• Injectable format may be a barrier for some
  
• Side effects possible, especially GI-related
  
  

Final Thoughts

Semaglutide represents a clinically studied , treatment option for those eligible under medical guidelines. AOD 9604 remains experimental and is not recommended for therapeutic use due to the lack of human trial validation.

Treatment decisions should always be guided by a licensed medical provider based on individual needs, history, and risk factors.

Disclaimer: Eden does not prescribe or dispense medications. We connect individuals with qualified healthcare providers who assess eligibility and offer guidance on treatment options. AOD 9604 is not FDA-approved for weight loss or any therapeutic use.

Learn More About GLP-1 Injections with Eden

‍